Antipas Marati
Neurology · Springfield, OHNPI 1427624147
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 253 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 36 manufacturers reported payments, led by AbbVie at 24.4% of the total. 2025 is the largest year on record at $2,009, 3.4 times the $586 reported in 2021.
Across 253 payments — averaging $29.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- MDD US Operations, LLC$534
- AstraZeneca$525
- SK Life Science, Inc.$458
- UCB, Inc.$457
- EMD Serono, Inc.$441
- plus $3K from 30 others
What the payments were for
- Food & beverage$7,490100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 56 | $1,829 |
| MDD US Operations, LLC | 35 | $534 |
| AstraZeneca(2 entities) | 10 | $525 |
| SK Life Science, Inc. | 18 | $458 |
| UCB, Inc. | 11 | $457 |
| EMD Serono, Inc. | 7 | $441 |
| Biogen | 11 | $371 |
| Novartis | 15 | $365 |
| Sanofi | 14 | $320 |
| Teva Pharmaceuticals USA, Inc. | 2 | $244 |
| Amneal Pharmaceuticals LLC | 7 | $243 |
| Neurocrine Biosciences, Inc. | 15 | $210 |
| Genentech USA, Inc. | 4 | $189 |
| Lundbeck LLC | 6 | $186 |
| Amgen(2 entities) | 4 | $138 |
| Eisai Inc. | 5 | $122 |
| Biohaven Pharmaceuticals, Inc. | 1 | $113 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $94 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $91 |
| Pfizer | 5 | $84 |
| Lilly USA, LLC | 4 | $77 |
| Acadia Pharmaceuticals Inc | 2 | $58 |
| Octapharma USA, Inc. | 2 | $45 |
| Jazz Pharmaceuticals Inc. | 2 | $44 |
| Kyowa Kirin, Inc. | 1 | $42 |
| TG Therapeutics, Inc. | 1 | $24 |
| Grifols USA, LLC | 1 | $23 |
| Philips North America LLC | 1 | $22 |
| Neurelis, Inc. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Merz Pharmaceuticals, LLC | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
| Amylyx Pharmaceuticals, Inc. | 1 | $18 |
| Acorda Therapeutics, Inc | 1 | $17 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $17 |
| Adamas Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,490 in reported general payments places this provider in the 70th percentile of 702 neurology providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Topiramate | 17 | $245 |
Paid to pharmacies, not to this prescriber.
Other neurology in Springfield
- Aram ZabetiCincinnati$1.6M
- Kenneth MankowskiColumbus$1.4M
- Aaron BosterColumbus$1.2M
- Martin TaylorNew Albany$821K
- Jacqueline NicholasColumbus$743K
- Lawrence ElmerToledo$687K
- Kenneth PugarCenterville$582K
- Brendan BauerSheffield Village$548K
- Geoffrey EubankColumbus$508K
- Lawrence GoldstickDayton$479K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.